Trial
NCT05158296
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Laboratoires Thea
Collaborators
Sepul Bio
Condition
Retinitis Pigmentosa
Intervention
Ultevursen
Why stopped
Business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-12